FDA Broadens Pitolisant Label - Top_Thought_Leaders - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Clinical Spectrum, independent risk factors, and treatment outcomes of pediatric arrhythmias: a multicenter retrospective analysis in Xinjiang

Insights into epidemiological and clinical burden of bronchiolitis among hospitalized children: a call for preventive interventions

Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies